Close Menu

local coverage determination

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

The Medicare contractor has proposed to cover the non-invasive test for certain kidney and heart transplant patients.

The company is forging ahead with its Signatera liquid biopsy circulating tumor DNA minimal residual disease (MRD) test and Prospera transplant assessment assay.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors. 

The Medicare contractor said in its draft guidance it would provide limited coverage for the cell-free DNA assay, which should be used as a supplemental test.

Medicare contractor Palmetto is proposing to expand coverage to ensure that more patients have access to genomic profiling when tissue-based testing is not possible.

CMS had received significant stakeholder feedback that germline NGS testing is not the same as somatic testing, and that the NCD as written would negatively impact patients.

Pages